IDiyas

For the Inventor, By the Inventor

Baltimore, MD, United States of America

Steven Fletcher

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 2.6

ph-index = 2

Forward Citations = 27(Granted Patents)


Company Filing History:

goldMedal13 out of 1,927 
 
University System of Maryland
 patents
silverMedal1 out of 1 
 
Mcdaniel College
 patent
bronzeMedal1 out of 1,862 
 
University of Pittsburgh
 patents
4. 1 out of 8 
 
Gen1e Lifesciences Inc.
 patents
where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 12404259 - Inhibitors of extracellular signal-regulated kinase (2025-09-02),
2. 12202810 - Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors (2025-01-21),
3. 11760752 - Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors (2023-09-19),
4. 11718595 - Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors (2023-08-08),
5. 11459313 - Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia (2022-10-04),
6. 11078171 - Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors (2021-08-03),
7. 10980811 - Reversal of fosfomycin resistance (2021-04-20),
8. 10961214 - Small molecule lipid II inhibitors (2021-03-30),
9. 10941114 - Small molecule lipid II inhibitors (2021-03-09),
10. 10858316 - Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof (2020-12-08),
11. 9242944 - Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability (2016-01-26),
12. 9115122 - Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK) (2015-08-25),
13. 8901164 - Amphipathic and other double-sided alpha-helix mimetics based on a 1,2-diphenylacetylene scaffold (2014-12-02),

Title: The Innovative Contributions of Steven Fletcher

Introduction

Steven Fletcher is a prominent inventor based in Baltimore, MD, with a remarkable portfolio of 13 patents. His work primarily focuses on pharmaceutical compositions and inhibitors that have significant implications for treating various diseases, including cancer and pulmonary conditions.

Latest Patents

Among his latest patents, Fletcher has developed inhibitors of extracellular signal-regulated kinase. One notable compound is 1,1-dioxido-2,3-dihydrothiophen-3-yl 4-phenoxybenzenesulfonate, which is used in pharmaceutical compositions for treating cancer and pulmonary diseases. Additionally, he has worked on non-ATP/catalytic site p38 mitogen-activated protein kinase inhibitors, which provide methods for treating or preventing diseases such as cancer and inflammatory conditions.

Career Highlights

Fletcher has had a distinguished career, contributing to significant advancements in the field of pharmaceuticals. He has worked with reputable institutions, including the University System of Maryland and McDaniel College, where he has been able to apply his innovative ideas and research.

Collaborations

Fletcher has collaborated with notable colleagues, including Paul S. Shapiro and Alexander D. MacKerell, Jr. Their combined expertise has likely enhanced the impact of his research and inventions.

Conclusion

Steven Fletcher's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work continues to pave the way for new treatments and therapies that can improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…